NASDAQ:ZIOP - Ziopharm Oncology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.51 0.00 (0.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$4.51
Today's Range$4.4915 - $4.58
52-Week Range$3.33 - $6.67
Volume564,940 shs
Average Volume1.42 million shs
Market Capitalization$626.24 million
P/E Ratio-8.51
Dividend YieldN/A
Beta1.74

About Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology logoZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970

Debt

Debt-to-Equity RatioN/A
Current Ratio7.17
Quick Ratio7.17

Price-To-Earnings

Trailing P/E Ratio-8.51
Forward P/E Ratio-8.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.39 million
Price / Sales100.68
Cash FlowN/A
Price / CashN/A
Book Value($0.86) per share
Price / Book-5.24

Profitability

EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-1,212.13%
Return on EquityN/A
Return on Assets-54.86%

Miscellaneous

Employees46
Outstanding Shares142,650,000

Ziopharm Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is Ziopharm Oncology's stock symbol?

Ziopharm Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were Ziopharm Oncology's earnings last quarter?

Ziopharm Oncology Inc (NASDAQ:ZIOP) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $0.15 million during the quarter, compared to the consensus estimate of $1.55 million. View Ziopharm Oncology's Earnings History.

When is Ziopharm Oncology's next earnings date?

Ziopharm Oncology is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Ziopharm Oncology.

What price target have analysts set for ZIOP?

2 brokerages have issued 12 month target prices for Ziopharm Oncology's stock. Their forecasts range from $5.50 to $5.50. On average, they expect Ziopharm Oncology's share price to reach $5.50 in the next twelve months. View Analyst Ratings for Ziopharm Oncology.

What are Wall Street analysts saying about Ziopharm Oncology stock?

Here are some recent quotes from research analysts about Ziopharm Oncology stock:
  • 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
  • 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)

Are investors shorting Ziopharm Oncology?

Ziopharm Oncology saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 34,594,585 shares, an increase of 3.0% from the April 30th total of 35,652,139 shares. Based on an average daily volume of 1,007,107 shares, the days-to-cover ratio is currently 34.4 days. Approximately 27.1% of the company's shares are sold short.

Who are some of Ziopharm Oncology's key competitors?

Who are Ziopharm Oncology's key executives?

Ziopharm Oncology's management team includes the folowing people:
  • Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
  • Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
  • Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
  • Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.

Has Ziopharm Oncology been receiving favorable news coverage?

News coverage about ZIOP stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ziopharm Oncology earned a news impact score of 0.21 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.65 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Ziopharm Oncology's major shareholders?

Ziopharm Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.92%), UBS Group AG (0.61%), Schwab Charles Investment Management Inc. (0.47%), Wells Fargo & Company MN (0.18%), Russell Investments Group Ltd. (0.16%) and Summit Trail Advisors LLC (0.09%). Company insiders that own Ziopharm Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for Ziopharm Oncology.

Which institutional investors are selling Ziopharm Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, BlackRock Inc., MetLife Investment Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Ziopharm Oncology.

Which institutional investors are buying Ziopharm Oncology stock?

ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., UBS Group AG, Summit Trail Advisors LLC, Mackay Shields LLC, Private Advisor Group LLC, Wealthcare Advisory Partners LLC, Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. Company insiders that have bought Ziopharm Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for Ziopharm Oncology.

How do I buy shares of Ziopharm Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ziopharm Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $4.51.

How big of a company is Ziopharm Oncology?

Ziopharm Oncology has a market capitalization of $626.24 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Ziopharm Oncology employs 46 workers across the globe.

How can I contact Ziopharm Oncology?

Ziopharm Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]


MarketBeat Community Rating for Ziopharm Oncology (ZIOP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Ziopharm Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ziopharm Oncology (NASDAQ:ZIOP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Ziopharm Oncology in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 21.95%. The high price target for ZIOP is $5.50 and the low price target for ZIOP is $5.50. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.50$10.00$16.50$16.25
Price Target Upside: 21.95% upside147.52% upside271.62% upside247.97% upside

Ziopharm Oncology (NASDAQ:ZIOP) Consensus Price Target History

Price Target History for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018HC WainwrightReiterated RatingBuy$5.50LowView Rating Details
12/11/2017Raymond JamesReiterated RatingHoldHighView Rating Details
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/AView Rating Details
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/10/2016Wells Fargo & CoUpgradeUnderperform ➝ Market PerformN/AView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 ➝ $5.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Ziopharm Oncology (NASDAQ:ZIOP) Earnings History and Estimates Chart

Earnings by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ:ZIOP) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.14)($0.14)($0.14)

Ziopharm Oncology (NASDAQ ZIOP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018        
5/10/2018Q1 2018($0.13)($0.15)$1.55 million$0.15 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.13)($0.13)$1.59 million$1.60 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
5/1/2017Q1 2017($0.12)($0.15)$1.71 million$1.60 millionViewListenView Earnings Details
2/16/2017Q4 2016($0.11)($0.11)$1.62 million$1.60 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)$1.82 million$1.92 millionViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)$57.70 million$0.27 millionViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$0.20 million$0.63 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.17)($0.18)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.25)($0.25)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.17)($0.18)ViewN/AView Earnings Details
7/30/2010Q2 2010($0.13)$0.19ViewN/AView Earnings Details
4/30/2010Q1 2010($0.10)($0.11)ViewN/AView Earnings Details
3/18/2010Q4 2009($0.12)$0.03ViewN/AView Earnings Details
11/11/2009Q3 2009($0.13)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.10)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.16)ViewN/AView Earnings Details
3/24/2009Q4 2008($0.19)($0.21)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.23)($0.26)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.36)($0.31)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.35)($0.41)ViewN/AView Earnings Details
2/22/2008Q4 2007($0.39)($0.36)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ziopharm Oncology (NASDAQ:ZIOP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 39.94%
Insider Trading History for Ziopharm Oncology (NASDAQ:ZIOP)
Institutional Ownership by Quarter for Ziopharm Oncology (NASDAQ:ZIOP)

Ziopharm Oncology (NASDAQ ZIOP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2017David M Md MauneyEVPBuy4,270$4.68$19,983.6058,662View SEC Filing  
11/8/2017Laurence James Neil CooperCEOBuy6,440$4.68$30,139.201,083,731View SEC Filing  
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ziopharm Oncology (NASDAQ ZIOP) News Headlines

Source:
DateHeadline
Ziopharm Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.20 MillionZiopharm Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.20 Million
www.americanbankingnews.com - May 24 at 5:50 AM
-$0.12 Earnings Per Share Expected for Ziopharm Oncology Inc (ZIOP) This Quarter-$0.12 Earnings Per Share Expected for Ziopharm Oncology Inc (ZIOP) This Quarter
www.americanbankingnews.com - May 22 at 5:22 AM
Ziopharm Oncology (ZIOP) Downgraded by BidaskClub to "Sell"Ziopharm Oncology (ZIOP) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - May 19 at 10:57 AM
Equities Analysts Offer Predictions for Ziopharm Oncology Incs Q3 2018 Earnings (ZIOP)Equities Analysts Offer Predictions for Ziopharm Oncology Inc's Q3 2018 Earnings (ZIOP)
www.americanbankingnews.com - May 17 at 7:00 AM
Head-To-Head Comparison: Ziopharm Oncology (ZIOP) vs. Horizon Pharma (HZNP)Head-To-Head Comparison: Ziopharm Oncology (ZIOP) vs. Horizon Pharma (HZNP)
www.americanbankingnews.com - May 17 at 5:19 AM
Ziopharm Oncology (ZIOP) Rating Lowered to Sell at Zacks Investment ResearchZiopharm Oncology (ZIOP) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 4:29 PM
New Research: Key Drivers of Growth for root9B Holdings Inc., Comfort Systems ...New Research: Key Drivers of Growth for root9B Holdings Inc., Comfort Systems ...
www.nasdaq.com - May 16 at 10:23 AM
Brokers Issue Forecasts for Ziopharm Oncology Incs FY2022 Earnings (ZIOP)Brokers Issue Forecasts for Ziopharm Oncology Inc's FY2022 Earnings (ZIOP)
www.americanbankingnews.com - May 16 at 8:20 AM
Ziopharm Oncology (ZIOP) Receives "Buy" Rating from HC WainwrightZiopharm Oncology (ZIOP) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 14 at 11:40 AM
Ziopharms Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You ThinkZiopharm's Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think
seekingalpha.com - May 14 at 11:06 AM
Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.
finance.yahoo.com - May 12 at 10:16 AM
BRIEF-Ziopharm Oncology Reports Q1 Loss Per Share $0.15BRIEF-Ziopharm Oncology Reports Q1 Loss Per Share $0.15
www.reuters.com - May 11 at 4:25 PM
Here's What's Causing Intrexon to Tumble 20% TodayHere's What's Causing Intrexon to Tumble 20% Today
finance.yahoo.com - May 11 at 4:25 PM
Ziopharm Q1 cash balance $51M; delays pivotal study of Ad-RTS-hIL-12 in glioblastoma; shares down 3% after hoursZiopharm Q1 cash balance $51M; delays pivotal study of Ad-RTS-hIL-12 in glioblastoma; shares down 3% after hours
seekingalpha.com - May 11 at 10:50 AM
ZIOPHARM Oncologys (ZIOP) CEO Laurence Cooper on Q1 2018 Results - Earnings Call TranscriptZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:50 AM
Edited Transcript of ZIOP earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of ZIOP earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:50 AM
Ziopharm: 1Q Earnings SnapshotZiopharm: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 10:50 AM
Ziopharm Oncology (ZIOP) Releases  Earnings Results, Misses Expectations By $0.02 EPSZiopharm Oncology (ZIOP) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 10 at 6:28 PM
Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate UpdateZiopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 4:17 PM
Ziopharm Oncology (ZIOP) to Release Quarterly Earnings on ThursdayZiopharm Oncology (ZIOP) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 9 at 11:45 AM
Ziopharm Oncology (ZIOP) Rating Increased to Hold at BidaskClubZiopharm Oncology (ZIOP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - May 9 at 8:52 AM
Ziopharm Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.55 MillionZiopharm Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.55 Million
www.americanbankingnews.com - May 6 at 2:06 AM
Zacks Investment Research Downgrades Ziopharm Oncology (ZIOP) to Strong SellZacks Investment Research Downgrades Ziopharm Oncology (ZIOP) to Strong Sell
www.americanbankingnews.com - May 5 at 8:09 PM
Ziopharm Oncology Inc (ZIOP) Expected to Post Earnings of -$0.13 Per ShareZiopharm Oncology Inc (ZIOP) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 4 at 10:03 PM
Ziopharm Oncology (ZIOP) Upgraded to Sell at ValuEngineZiopharm Oncology (ZIOP) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - May 2 at 1:15 PM
Ziopharm Oncology (ZIOP) Lowered to "Sell" at BidaskClubZiopharm Oncology (ZIOP) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 19 at 10:42 AM
 Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Announce Quarterly Sales of $1.55 Million Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Announce Quarterly Sales of $1.55 Million
www.americanbankingnews.com - April 19 at 2:28 AM
Ziopharm Oncology (ZIOP) Stock Rating Upgraded by ValuEngineZiopharm Oncology (ZIOP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:21 PM
-$0.13 EPS Expected for Ziopharm Oncology Inc (ZIOP) This Quarter-$0.13 EPS Expected for Ziopharm Oncology Inc (ZIOP) This Quarter
www.americanbankingnews.com - April 17 at 7:27 PM
Ziopharm Oncology (ZIOP) Given a $10.00 Price Target at HC WainwrightZiopharm Oncology (ZIOP) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 14 at 3:36 PM
Ziopharm Oncology (ZIOP) Raised to Hold at BidaskClubZiopharm Oncology (ZIOP) Raised to Hold at BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM
Ziopharm Oncology (ZIOP) Downgraded by ValuEngine to SellZiopharm Oncology (ZIOP) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 10 at 4:28 PM
Ziopharm Oncology (ZIOP) Stock Rating Upgraded by BidaskClubZiopharm Oncology (ZIOP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Global Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene CorporationGlobal Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene Corporation
www.marketwatch.com - April 4 at 5:22 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.55 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.55 Million
www.americanbankingnews.com - April 2 at 2:12 AM
Edited Transcript of ZIOP earnings conference call or presentation 1-Mar-18 9:30pm GMTEdited Transcript of ZIOP earnings conference call or presentation 1-Mar-18 9:30pm GMT
finance.yahoo.com - April 1 at 9:51 AM
Zacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) Will Post Earnings of -$0.13 Per ShareZacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - March 31 at 7:12 PM
ZIOPHARM Oncology (ZIOP) Rating Increased to Sell at BidaskClubZIOPHARM Oncology (ZIOP) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 30 at 5:08 PM
Financial Analysis: ZIOPHARM Oncology (ZIOP) vs. Immune Design (IMDZ)Financial Analysis: ZIOPHARM Oncology (ZIOP) vs. Immune Design (IMDZ)
www.americanbankingnews.com - March 23 at 7:08 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 Million
www.americanbankingnews.com - March 16 at 3:44 AM
Zacks Investment Research Downgrades ZIOPHARM Oncology (ZIOP) to SellZacks Investment Research Downgrades ZIOPHARM Oncology (ZIOP) to Sell
www.americanbankingnews.com - March 15 at 12:50 PM
-$0.13 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter-$0.13 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - March 14 at 5:24 PM
Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7%Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7%
www.americanbankingnews.com - March 12 at 2:14 AM
ZIOPHARM Oncology (ZIOP) Raised to "Hold" at Zacks Investment ResearchZIOPHARM Oncology (ZIOP) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 9 at 9:02 PM
ZIOPHARM Oncology, Inc. 2017 Q4 - Results - Earnings Call SlidesZIOPHARM Oncology, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 5 at 4:25 PM
ZIOPHARM Oncology (ZIOP) Earns Buy Rating from HC WainwrightZIOPHARM Oncology (ZIOP) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - March 5 at 11:48 AM
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues BeatIntrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - March 2 at 4:13 PM
ZIOPHARM Oncology (ZIOP) Downgraded to "Strong Sell" at ValuEngineZIOPHARM Oncology (ZIOP) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 1 at 11:30 PM
ZIOPHARM Oncology (ZIOP) Announces  Earnings ResultsZIOPHARM Oncology (ZIOP) Announces Earnings Results
www.americanbankingnews.com - March 1 at 9:12 PM
Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateZiopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 1 at 4:19 PM

SEC Filings

Ziopharm Oncology (NASDAQ:ZIOP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ziopharm Oncology (NASDAQ:ZIOP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ziopharm Oncology (NASDAQ ZIOP) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.